Biotalys NV

As of June 30, 2026, Biotalys NV carries a market capitalization of 140.65M, placing it among publicly traded companies globally. Its enterprise value stands at 129.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biotalys NV's next confirmed earnings release is scheduled for March 5, 2027.

As of June 30, 2026, Biotalys NV has 45.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Biotalys NV maintains a current ratio of 2.93, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Biotalys NV's stock has declined approximately 62.50% over the past 52 weeks. The 50-day moving average sits at 2.11, while the 200-day moving average is 2.60.

As of June 30, 2026, Biotalys NV holds 14.04M in cash and equivalents against 3.24M in total debt, resulting in a net debt position of -11.93M. Total book value stands at 14.97M, with working capital of 10.22M providing operational flexibility.